From discovery to treatment

Coretag’s most advanced clinical candidates, CyanTag® and CyanCore®, have physical half-lives of approximately 1 hour and 9 hours, respectively. Each compound is composed of a cyanine conjugated to a chelator (like DOTA or DOTAGA). The diagnostic and therapeutic radioisotopes prioritized to be used for our Phase 1a/b clinical trial, are Copper-64 and Lutetium-177, respectively.